Print Table

Flexible Options Are Available for Ordering JETREA®

Authorized Specialty Distributors and Specialty Pharmacies Phone Number Shipping Schedule
Please note that due to the storage and handling requirements of JETREA, shipping will only occur Monday through Thursday, for next day delivery.
Besse Medical (888) 767-7123
McKesson Biologics & Plasma (877) 625-2566
McKesson Specialty Health (800) 482-6700
AllianceRx Walgreens Prime Phone: (888) 347-3416
Fax: (866) 586-7804


Additional Flexibility Offered

Convenient Payment Options

  • Credit cards accepted

Product Replacement Program

  • Returns Goods Policy for Healthcare Providers
    click here
  • For more information call (855) TRY-JETREA (879-5387) [Option 3]
ThromboGenics® has provided their distributor partners with payment terms. Based on distributor eligibility criteria, your office may qualify to receive these payment terms. Please contact your distributor partner for details.

Product Information Highlights

NDC number
Wholesale Acquisition Cost (WAC) Description Contents
24856-0002-01 $2,963.00 JETREA® (ocriplasmin) injection, for Intravitreal Injection Single-use vial. Do not dilute. Each vial of JETREA contains 0.375 mg ocriplasmin in 0.3 mL preservative-free, citric-buffered solution (1.25 mg/ mL).
Storage and Handling

  • JETREA is stored frozen at or below -4°F (-20°C) out of direct light
  • Prior to shipment, a practice will need to confirm that it has a freezer with the ability to meet the required temperature of -20°C
  • JETREA will be shipped with dry ice coolant
  • The expiration date is printed on each dispensing pack and vial label


JETREA (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

Adverse Reactions

  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Please see full Prescribing Information for JETREA.

You are encouraged to report side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Health Care Professional.

For medical information inquiries, or to report an adverse event or product-related complaint, please call 1-855-253-7396 or email